AbCellera vs Finch Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.
About
AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.
Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis with programs in autism spectrum disorder and C. difficile.
About
Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic diseases. The company is focused on two primary therapeutic areas: gastrointestinal infections including C. difficile and conditions involving the gut-brain axis including autism spectrum disorder where gut microbiome alterations have been associated with symptom severity. Finch's lead microbiome program CP101 targets recurrent C. difficile infection, competing in the same emerging microbiome therapeutics space as Seres Therapeutics. The company also conducts research on the COMET platform for autism spectrum disorder, exploring whether microbiome restoration can improve behavioral symptoms through the gut-brain connection. Finch has raised over $165M and has conducted multiple clinical trials of its microbiome medicines. The company's autism program represents a particularly innovative and scientifically ambitious program given the emerging evidence that gut microbiome composition influences neurological development and behavior. Finch's work contributes to the broader scientific validation of microbiome medicine as a legitimate therapeutic class beyond C. difficile.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.